+977-01-5321512 / 5350794
  • लिमिटेडको तर्फवाट समेत सहभागिता जनाइएको USAID – PQM+ को सहयोगमा Department of Health Services (Management Division) द्वारा आयोजित Dissemination on Leadership, Management and Governance Approach on Quality Assurance of Medical Products in Local Governments कार्यक्रम समापन पछि सामूहिक तस्विरमा सहभागिहरु ।

  • मिति २०८१।०४।२९ मा लिमिटेड भ्रमणका क्रममा माननीय स्वास्थ्य तथा जनसंख्या मन्त्री श्री प्रदीप पौडेल ज्यू समक्ष लिमिटेडका विविध पक्षवारे अवगत गराउनुहुँदै लिमिटेडका महाप्रवन्धक तथा अन्य पदाधिकारीहरु ज्यूहरु ।

  • मिति २०८१।०४।२५ मा नेपाल औषधि लिमिटेड र टर्किश दातृ संस्था; Turkish Cooperation and Coordination Agency (TiKA) बिच सहकार्यका विषयमा छलफल पश्चात सामूहिक फोटोमा लिमिटेडका पदाधिकारी तथा TiKA का प्रतिनिधिहरु ।

  • लिमिटेडको ५०औं वार्षिक साधारण सभा सम्पन्न भए पश्चात सामूहिक तस्विर खिचाउँदै लिमिटेडका शेयरधनी प्रतिनिधिज्यूहरु, संचालक समिति सदस्यज्यूहरु र साथमा लिमिटेडका कर्मचारीहरु ।

  • लिमिटेडको ५०औं वार्षिक साधारण सभाको छलफल सत्रमा सहभागी लिमिटेडका शेयरधनी प्रतिनिधि तथा लिमिटेडका पदाधिकारीज्यूहरु ।

  • मिति २०८१ जेठ ३० गते उद्योग, वाणिज्य तथा आपूर्ति मन्त्रालयको सभाहल, सिंहदरवार, काठमाण्डौंमा लिमिटेडको ५०औं वार्षिक साधारण सभाको उद्घाटन गर्नुहुँदै संचालक समितिका अध्यक्ष श्री यज्ञ प्रसाद न्यौपाने ज्यू ।

  • अन्तर्गतको USP-PQM+ कार्यक्रम द्वारा २०८१ बैशाख १२ र १३ (April 24-25, 2024) मा संचालित Training on Good Manufacturing Practices (GMP) सम्पन्न भए पश्चात सहभागिहरुसँग सामूहिक तस्विर खिचाउँदै लिमिटेडका पदाधिकारी तथा कर्मचारीहरु ।

  • USAID अन्तर्गतको USP-PQM+ कार्यक्रम द्वारा २०८१ बैशाख १२ र १३ (April 24-25, 2024) मा संचालित Training on Good Manufacturing Practices (GMP) सम्पन्न भए पश्चात समापन मन्तव्य दिनु हुँदै लिमिटेडका महाप्रवन्धक कैलाश कुमार पनेरु ज्यू ।

  • USAID अन्तर्गतको USP-PQM+ कार्यक्रम द्वारा २०८१ बैशाख १२ र १३ (April 24-25, 2024) मा संचालित Training on Good Manufacturing Practices (GMP) सहभागी लिमिटेडका कर्मचारीहरु ।

  • ARDIFOLIC

  • Tablets

  • Distilled Water

  • Jeevan Jal

  • Sanitiz

  • Cetamol Tablets

Objectives

The primary objective of the company was to manufacture various pharmaceutical dosage forms to meet requirements of the nation. In specific the company aimed: To manufacture allopathic medicines for the requirement of the country To carry out quality control of imported products To contribute for the quality assurance of the marketed products To supply medicine to the general public in an affordable price To play vital role by substituting import...

Read More
About us

Nepal Aushadhi Limited

"A PIONEER PHARMACEUTICAL INDUSTRY OF NEPAL" Nepal Aushadhi Limited a government enterprise established in 2029 under the company Act, 2021 with the help of technical collaboration of the British Government in the form of expertise & equipment, and become a milestone in the pharmaceutical industry of the nation. The company was an extension of Formulation Unit of Royal Drug Research Laboratory (now National Medicine Laboratory under Department of Drug Administration) which was under Department of Medicinal Plant/Ministry of Forest. Technical experts for formulation of medicine, pharmacists, under the research laboratory were shifted to Royal Drugs Limited for production and quality...

Read More

Nepal Aushadhi Limited and USAID together for ‘quality-assured medicines’

USAID, PQM+ को आयोजनामा 'Role of public manufacturer to ensure...

Business Meeting

High Hope International Group, China को व्यावसायिक प्रतिनिधि मण्डल सँग...

#CSR Initiative of NAL

यही २०८१ कार्तिक २१ र २२ गते यस नेपाल औषधि...

Message from General Manager

MR. KAILASH KUMAR PANERU

For 50 years now, NAL has built a unique position in the Nepalese healthcare system. In the field of pharmaceutics, and I am pleased to play a part as General Manager. One of the primary roles of pharmaceutical industry is to foster excellence in production, quality assurance and research. It is a role that we take very seriously here at NAL, reflected well in short and long term plan.

The immediate plan shall be executed to start manufacturing its popular brand Cetamol (paracetamol) tablet and Jeevan Jal (Oral Rehydration Salt). Both the products are in essential drug list and there is a good demand for general public at health post and sub health post level. For manufacturing the products, the existing tablet area will be modified; incorporating clean room concepts for maintaining class 100000 conditions at primary processing area. Quality control will be strengthened to quality assurance system in compliance with CGMP standard. Once the initial startup of the tablet section is commenced and the process is continued with additional products, the long-term master plan shall also be implemented to create additional facilities for further development.

0